Navigation Links
Avanir Pharmaceuticals Reports Fiscal 2011 Third Quarter Financial Results
Date:8/8/2011

re to evaluate the safety, tolerability and efficacy of three dose levels of AVP-923 capsules for the treatment of central neuropathic pain in a population of patients with multiple sclerosis.
  • In August, the company announced the appointment of Dr. Joao Siffert as senior vice president research & development.

  • Cash, Cash Equivalents & Marketable SecuritiesAs of June 30, 2011 Avanir had cash, cash equivalents and investments in securities totaling $93.5 million, including cash and cash equivalents of $91.3 million and restricted investments in securities of $2.2 million.

    Note to Investors: As previously announced, Avanir will hold a conference call to discuss fiscal 2011 third quarter financial results today, August 8, 2011, beginning at 1:30 p.m. Pacific Time. You can listen to this call by dialing 1-877-558-3407 for domestic callers or +1-706-679-1941 for international callers, and entering passcode 87076138. Those interested in listening to the conference call live via the internet may do so by visiting http://www.avanir.com.

    About NUEDEXTANUEDEXTA® is the first and only FDA-approved treatment for pseudobulbar affect (PBA). NUEDEXTA is an innovative combination of two well-characterized components; dextromethorphan hydrobromide (20 mg), the ingredient active in the central nervous system, and quinidine sulfate (10 mg), a metabolic inhibitor enabling therapeutic dextromethorphan concentrations. NUEDEXTA acts on sigma-1 and NMDA receptors in the brain, although the mechanism by which NUEDEXTA exerts therapeutic effects in patients with PBA is unknown.

    NUEDEXTA is indicated for the treatment of pseudobulbar affect (PBA). PBA occurs secondary to a variety of otherwise unrelated neurological conditions, and is characterized by involuntary, sudden, and frequent episodes of laughing and/or crying. PBA episodes typically occur out of proportion or incongruent to the pati
    '/>"/>

    SOURCE Avanir Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. AVANIR Pharmaceuticals Invites Investors to Fiscal 2010 Third Quarter Conference Call
    2. AVANIR Pharmaceuticals to Present at the UBS Global Life Sciences Conference
    3. AVANIR Pharmaceuticals Announces FDA Approval of NUEDEXTA™
    4. AVANIR Pharmaceuticals Invites Investors to Conference Call Regarding FDA Approval of NUEDEXTA™ on Monday November 1, 2010
    5. AVANIR Pharmaceuticals Announces Pricing of Public Offering of Common Stock
    6. AVANIR Pharmaceuticals Announces NASDAQ Opening Bell Ceremony
    7. AVANIR Pharmaceuticals Invites Investors to Fiscal 2011 First Quarter Conference Call
    8. AVANIR Pharmaceuticals Announces Fiscal 2011 First Quarter Financial Results
    9. AVANIR Pharmaceuticals Appoints Gregory J. Flesher to Senior Vice President and Chief Business Officer
    10. Avanir Pharmaceuticals to Present at Three Conferences in March
    11. Avanir Pharmaceuticals to Present at BioCentury Future Leaders in the Biotech Industry Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)... 2014 Soligenix, Inc. (OTCQB: SNGX) (Soligenix ... products that address unmet medical needs in the ... that on December 24, 2014 it closed its ... Company raised approximately $2.3 million in gross proceeds ... net proceeds from the offering to fund its ...
    (Date:12/24/2014)... , December 24, 2014 ... at an average rate of 8.1%. The US has ... knee and spine surgeries are the common orthopedic procedures ... have a lower penetration. Increased number of product recalls ... Non-metallic orthopedic devices have gained popularity in the industry ...
    (Date:12/24/2014)... , December 24, 2014 ... on Global Disposable Syringe Industry of 178 ... online business intelligence library. The ... Syringe Industry is a professional and deep ...  For overview analysis, the report introduces Disposable ...
    Breaking Medicine Technology:Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 2World Disposable Syringe Market 2014 Report: China and Regional Analysis 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 4World Disposable Syringe Market 2014 Report: China and Regional Analysis 5
    ... Reserve" May Also Affect,Alzheimer's Risk -, WASHINGTON, June ... treating risk factors for heart disease and stroke,such ... the progression,of Alzheimer's disease, according to research reported ... Prevention,of Dementia in Washington, DC. , Two new ...
    ... Jun 09, 2007 (MARKET WIRE via COMTEX ... owned subsidiary of Endo,Pharmaceuticals Holdings Inc. (NASDAQ: ... randomized, double-blind, placebo-controlled,clinical trial evaluating Frova (frovatriptan ... treatment in women with,difficult-to-treat menstrual migraine (MM). ...
    Cached Medicine Technology:Treating Heart Disease Risk Factors May Slow Alzheimer's Disease,Progression 2Treating Heart Disease Risk Factors May Slow Alzheimer's Disease,Progression 3Treating Heart Disease Risk Factors May Slow Alzheimer's Disease,Progression 4Treating Heart Disease Risk Factors May Slow Alzheimer's Disease,Progression 5Treating Heart Disease Risk Factors May Slow Alzheimer's Disease,Progression 6Treating Heart Disease Risk Factors May Slow Alzheimer's Disease,Progression 7Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 2Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 3Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 4Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 5Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 6Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 7
    (Date:12/26/2014)... Abilene, Texas (PRWEB) December 26, 2014 Yisrayl ... has written an open letter in light of the Ferguson, ... year history of civil unrest and explains why it has ... the reason mankind was even created. He says there is ... in detail. Yisrayl also says there is a set of ...
    (Date:12/26/2014)... 26, 2014 “Many people become overwhelmed ... injury claim issues and phone calls with insurance companies,” ... article featuring their free eBook on pedestrian and ... on pedestrian and bicycle auto accident claims assures the ... capable of professionally handling their case while they focus ...
    (Date:12/26/2014)... 26, 2014 DW-InductionHeating.com (DaWei Induction Heating ... researching and developing, producing and marketing of a series ... business announces their new series of induction brazing ... the company, induction brazing refers to the ... filler material and heat. The manager says that there ...
    (Date:12/25/2014)... This is a professional and in-depth ... industry with a focus on the Chinese market. The ... the Sterilizers manufacturers and is a valuable source of ... the industry. This report provides a basic overview of ... In this part, the report presents the company profile, ...
    (Date:12/25/2014)... Dallas, TX (PRWEB) December 26, 2014 ... Analysis to 2023” focuses on the current treatment landscape, ... colorectal cancer market. TS-1 is an anti-cancer drug which ... administered orally and is also used for treating gastric ... gimestat and otastat potassium. The drug was first approved ...
    Breaking Medicine News(10 mins):Health News:Yisrayl Hawkins Pleads for Peace in Ferguson and Beyond in New Open Letter 2Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3
    ... 25 The HHS Office of HIV/AIDS Policy,s AIDS.gov will ... with a special focus on reducing HIV/AIDS-related stigma and promoting ... World AIDS Day will also mark the second anniversary of ... and resources. , , AIDS.gov ...
    ... guide treatment choices, researchers say , , TUESDAY, Nov. 25 ... genetic model for predicting the risk of recurrence in ... a team at the Duke Institute for Genome Science ... to chemotherapy and targeted therapy regimens. , The researchers ...
    ... available in Spanish . , A new ... the first time since the report was first issued in ... are decreasing for both men and women, driven largely by ... The report notes that, although the decreases in overall ...
    ... , , HARRISBURG, Pa., Nov. ... West Middlesex Area School District, the Pennsylvania Department of Health ... Middlesex Junior/Senior High School on Nov. 19 and Nov. 24. ... tetanus/diphtheria/pertussis vaccine was given to approximately 560 parents, students, and ...
    ... Gen-Probe Incorporated,(Nasdaq: GPRO ) announced today that the ... Conference on Tuesday, December 2, 2008 at,noon Eastern Time. The ... through a link on the investors section of Gen-Probe,s website ... days following,the event. , ...
    ... with chronic obstructive pulmonary disorder must weigh risks, benefits, ... A new review of existing data confirms that some ... with the lung disease known as chronic obstructive pulmonary ... raise the risk of pneumonia in patients with COPD, ...
    Cached Medicine News:Health News:HHS' AIDS.gov to Use Blogs, Virtual Worlds, and Social Networks to Deliver HIV Information for World AIDS Day 2008 2Health News:Gene Test Could Predict Colon Cancer's Return 2Health News:Annual report to the nation finds declines in cancer incidence and death rates 2Health News:Annual report to the nation finds declines in cancer incidence and death rates 3Health News:Annual report to the nation finds declines in cancer incidence and death rates 4Health News:Annual report to the nation finds declines in cancer incidence and death rates 5Health News:Gen-Probe to Webcast Presentation at the 20th Annual Piper Jaffray Health Care Conference 2Health News:Steroid Inhalers Raise Pneumonia Risk for Lung Disease Patients 2Health News:Steroid Inhalers Raise Pneumonia Risk for Lung Disease Patients 3
    ... a scientifically advanced multinutrient that ... and full body health. It ... including a diverse array of ... lycopene and OptiBerry and important ...
    ... Ocuvite® Extra vitamin and mineral supplements ... original formula plus more. Ocuvite ... and higher levels of vitamins C ... also contains other antioxidants and minerals ...
    HydroEye is an exclusive formulation designed to provide dry eye relief and support the body's natural tear formation. Like all ScienceBased Health formulations, it is produced in softgel form for ma...
    Expert QC data management solution...
    Medicine Products: